UB Paderborn / Katalog / Suche / in CDI

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Journal of medicinal chemistry, 2019-02, Vol.62 (4), p.1715-1730

2019

Volltextzugriff (PDF)

A new predictive biomarker enables more accurate PD-1 blockade therapy

Cellular & molecular immunology, 2021-07, Vol.18 (7), p.1624-1625

2021

Volltextzugriff (PDF)

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer

Journal of medicinal chemistry, 2018-08, Vol.61 (16), p.6983-7003

2018

Volltextzugriff (PDF)

The development of small-molecule inhibitors targeting HPK1

European journal of medicinal chemistry, 2022-12, Vol.244, p.114819-114819, Article 114819

2022

Volltextzugriff (PDF)

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Journal of medicinal chemistry, 2021-06, Vol.64 (11), p.7390-7403

2021

Volltextzugriff (PDF)

Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer

Journal of medicinal chemistry, 2023-01, Vol.66 (1), p.1027-1047

2023

Volltextzugriff (PDF)

Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma‑b (Cbl-b)

Journal of medicinal chemistry, 2024-01, Vol.67 (2), p.816-837

2024

Volltextzugriff (PDF)

Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors

Journal of medicinal chemistry, 2023-04, Vol.66 (7), p.4378-4416

2023

Volltextzugriff (PDF)

Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V‑Domain Ig Suppressor of T‑Cell Activation (VISTA)

Journal of medicinal chemistry, 2023-09, Vol.66 (17), p.11881-11892

2023

Volltextzugriff (PDF)

Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy

Journal of medicinal chemistry, 2023-12, Vol.66 (24), p.16807-16827

2023

Volltextzugriff (PDF)

Development of Inhibitors Targeting the V‑Domain Ig Suppressor of T Cell Activation Signal Pathway

Journal of medicinal chemistry, 2022-09, Vol.65 (18), p.11900-11912

2022

Volltextzugriff (PDF)

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery

European journal of medicinal chemistry, 2023-10, Vol.258, p.115607-115607, Article 115607

2023

Volltextzugriff (PDF)

Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer

Journal of medicinal chemistry, 2022-06, Vol.65 (11), p.7746-7769

2022

Volltextzugriff (PDF)

Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold

European journal of medicinal chemistry, 2023-08, Vol.256, p.115468-115468, Article 115468

2023

Volltextzugriff (PDF)

Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors

European journal of medicinal chemistry, 2023-03, Vol.250, p.115217-115217, Article 115217

2023

Volltextzugriff (PDF)

Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction

RSC advances, 2021-07, Vol.11 (38), p.2327-23279

2021

Volltextzugriff (PDF)

Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro)

European journal of medicinal chemistry, 2023-09, Vol.257, p.115487-115487, Article 115487

2023

Volltextzugriff (PDF)

Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia

Journal of medicinal chemistry, 2024-01, Vol.67 (2), p.1513-1532

2024

Volltextzugriff (PDF)

Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer

Bioorganic & medicinal chemistry letters, 2019-06, Vol.29 (12), p.1502-1506

2019

Volltextzugriff (PDF)

Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1

RSC medicinal chemistry, 2024-04, Vol.15 (4), p.196-118

2024

Volltextzugriff (PDF)

Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)

Journal of medicinal chemistry, 2021-04, Vol.64 (7), p.4020-4033

2021

Volltextzugriff (PDF)

Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer

European journal of medicinal chemistry, 2021-02, Vol.211, p.113022, Article 113022

2021

Volltextzugriff (PDF)

Design, Synthesis, and Evaluation of PD-1/PD-L1 Antagonists Bearing a Benzamide Scaffold

ACS medicinal chemistry letters, 2022-04, Vol.13 (4), p.586-592

2022

Volltextzugriff (PDF)

Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1

Bioorganic chemistry, 2023-09, Vol.138, p.106682-106682, Article 106682

2023

Volltextzugriff (PDF)

Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells

Future medicinal chemistry, 2020-02, Vol.12 (4), p.311-323

2020

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

A new predictive biomarker enables more accurate PD-1 blockade therapy

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer

The development of small-molecule inhibitors targeting HPK1

Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer

Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma‑b (Cbl-b)

Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors

Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V‑Domain Ig Suppressor of T‑Cell Activation (VISTA)

Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy

Development of Inhibitors Targeting the V‑Domain Ig Suppressor of T Cell Activation Signal Pathway

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery

Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer

Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold

Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors

Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction

Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro)

Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia

Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer

Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1

Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC)

Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer

Design, Synthesis, and Evaluation of PD-1/PD-L1 Antagonists Bearing a Benzamide Scaffold

Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1

Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells

Suchergebnisse filtern